Suggested remit: To appraise the clinical and cost effectiveness of atezolizumab monotherapy within its marketing authorisation for untreated advanced non-small-cell lung cancer.
Status In progress
Process STA 2018
ID number 1678

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
07 January 2020 - 04 February 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
13 February 2018 In progress, DHSC referral received

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance